Am J Transplant, Volume 16, Suppl 3 Archives - Page 133 of 180 - ATC Abstracts

2016 American Transplant Congress
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).
B. Shin, J. Choi, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel IS agent that acts through costimulatory blockade of T-cells and obviates the need for CNI. Despite benefits in improving renal…
2016 American Transplant Congress
Impact of the Kidney Allocation System with Deceased Donor Kidney Utilization at the DSA Level.
W. Ally,² C. Saunders,¹ K. Brayman,² A. Agarwal.²
¹Lifenet Health, Virginia Beach, VA; ²University of Virginia Health System, Charlottesville, VA.
Background: In December 2014, UNOS implemented broad sweeping changes in the new Kidney Allocation System (KAS). Recent summary reports by UNOS suggest that on a…
2016 American Transplant Congress
25-Hydroxyvitamin D Insufficiency Is Associated with Higher Risk of BK Virus Re-Activation After Kidney Transplantation.
N. Elfadawy,¹ S. Flechner,² E. Poggio,² B. Stephany,² R. Fatica,² J. Schold,² S. Mossad.²
¹Internal Medicine, Case Western Reserve University, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH.
BACKGROUND: The past decade has seen increased interest in vitamin D, as new data suggest that it plays a role in the immune system. The…
2016 American Transplant Congress
Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation.
X. Cheng,¹ M. Stedman,¹ W. Kim,² J. Tan.¹
¹Division of Nephrology, Stanford University, Palo Alto, CA; ²Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA.
The number of simultaneous liver-kidney transplants (SLKT) for end-stage liver disease (ESLD) with renal failure is rising. The overall utility of kidneys used in this…
2016 American Transplant Congress
Clinical Prediction Tool to Guide Referral of Elderly Dialysis Patients for Kidney Transplant Evaluation.
L.-X. Chen,¹ M. Josephson,¹ N. Stankus,¹ K. Campbell,¹ D. Hedeker,² M. Saunders.¹
¹Department of Medicine, University of Chicago, Chicago, IL; ²Department of Public Health Sciences, University of Chicago, Chicago, IL.
Background: Adults over 70 years old are the fastest growing segment of the end stage renal disease (ESRD) population. Due to substantial variation in co-morbidities…
2016 American Transplant Congress
Mortality and Graft Loss Attributable to Readmission Following Kidney Transplantation.
E. King, M. Bowring, L. Kucirka, M. McAdams-DeMarco, A. Massie, D. Segev.
Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.
BACKGROUND: Early hospital readmission (EHR) following kidney transplantation (KT) is independently associated with graft loss and mortality. Prior work assumes that this association is constant…
2016 American Transplant Congress
Pre-Transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-Transplant Outcomes: A National Study.
M. Nazzal,¹ J. Chen,¹ K. Lentine,¹ M. Schnitzler,¹ J. Tuttle-Newhall,² C. Varma,¹ A. Taha,¹ A. Said,¹ H. Xiao,¹ H. Randall.¹
¹Saint Louis Univ, Saint Louis; ²East Carolina Univ, Greenville.
Currently most transplant centers use loco-regional therapy to bridge liver transplant (LT) candidates with hepatocellular carcinoma (HCC). However, limited data are available to support the…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
The Impact of Share 35 on Liver Allocation and Utilization: One DSA's Experience.
J. Orlowski, C. Muse, J. Whaley, R. Squires.
LifeShare of Oklahoma, Oklahoma City, OK.
Background: In June 2013, U.S. liver allocation changed from a local-regional-national model to “Share 35”, broadening sharing to a regional level based upon recipient MELD…
2016 American Transplant Congress
Mechanisms of Alloantigen-Specific Regulation After Donor Specific Transfusion and Costimulatory Blockade in YFP-Foxp3/TdTomRed-Ebi3 Marker Mice.
Y. Tomita,¹ W. Bracamonte-Baran,¹ D. Vignali,² W. Burlingham.¹
¹Department of Surgery, Division of Transplantation, University of Wisconsin-Madison, Madison, WI; ²Department of Immunology, University of Pittsburgh, Pittsburgh.
Background: In mice, donor specific transfusion (DST) plus anti-CD40L costimulatory blockade (MR-1) treatment is a standard and successful protocol to induced donor-specific transplant tolerance. Hypothesis:…